Novo Nordisk A/S (NYSE:NVO) Earns Equal Weight Rating from Analysts at Morgan Stanley

Investment analysts at Morgan Stanley initiated coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a research note issued on Wednesday,Briefing.com Automated Import reports. The firm set an “equal weight” rating on the stock.

Other equities analysts also recently issued reports about the company. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $83.78 on Wednesday. The business’s 50 day moving average price is $90.96 and its 200-day moving average price is $110.91. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The firm has a market capitalization of $375.95 billion, a PE ratio of 25.46, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Several institutional investors and hedge funds have recently bought and sold shares of NVO. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $28,000. Center for Financial Planning Inc. raised its stake in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $48,000. Finally, Dunhill Financial LLC increased its holdings in shares of Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after purchasing an additional 311 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.